Keros Therapeutics Inc (KROS)

03:07 AM

What drives Keros Therapeutics Inc. stock priceFree Stock Market Mentorship - Autocar Professional

03:07 AM

Jul 19, 2025

What analysts say about Keros Therapeutics Inc. stockOutstanding capital growth - Jammu Links News

Jul 19, 2025

Jul 18, 2025

Keros Therapeutics Inc. Stock Analysis and ForecastFree Investment Case Studies - Jammu Links News

Jul 18, 2025

Jul 18, 2025

Should I buy Keros Therapeutics Inc. stock before earningsHigh Confidence Trade Setups - Newser

Jul 18, 2025

Jul 17, 2025

Keros Therapeutics Begins Phase 3 Trial for Elritercept - TipRanks

Jul 17, 2025

Jul 17, 2025

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept - The Manila Times

Jul 17, 2025

Jul 17, 2025

Keros Therapeutics doses first patient in Phase 3 MDS trial - Investing.com

Jul 17, 2025

Jul 17, 2025

Keros Therapeutics doses first patient in Phase 3 MDS trial By Investing.com - Investing.com UK

Jul 17, 2025

Jul 16, 2025

Why Keros Therapeutics Inc. stock attracts strong analyst attentionLow Drawdown Trade Signals - Newser

Jul 16, 2025

Jul 16, 2025

How Keros Therapeutics Inc. stock performs during market volatilityFree Signals Group - Newser

Jul 16, 2025

Jul 15, 2025

What makes Keros Therapeutics Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser

Jul 15, 2025

Jul 09, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Average Target Price from Brokerages - MarketBeat

Jul 09, 2025

Jul 09, 2025

Trend Tracker for (KROS) - news.stocktradersdaily.com

Jul 09, 2025

Jul 08, 2025

Sarcopenia Market Expected to Experience Major Growth by 2034, According to DelveInsight | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross - Barchart.com

Jul 08, 2025

Jul 06, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Jul 06, 2025

Jun 30, 2025

Keros Therapeutics, Inc.(NasdaqGM: KROS) dropped from Russell 3000 Growth Index - MarketScreener

Jun 30, 2025

Jun 30, 2025

Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Value Index - MarketScreener

Jun 30, 2025

Jun 18, 2025

(KROS) Trading Report - news.stocktradersdaily.com

Jun 18, 2025

Jun 17, 2025

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN

Jun 17, 2025

Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025

Jun 14, 2025

Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56 - MarketBeat

Jun 14, 2025

Jun 13, 2025

Bank of America Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat

Jun 13, 2025

Jun 13, 2025

Two Sigma Investments LP Buys 23,342 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jun 13, 2025

Jun 12, 2025

Keros Therapeutics (NASDAQ:KROS) Shares Gap DownTime to Sell? - MarketBeat

Jun 12, 2025

Jun 11, 2025

Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Bank of America - Defense World

Jun 11, 2025

Jun 11, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 11, 2025

Jun 10, 2025

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Benzinga

Jun 10, 2025

Jun 10, 2025

Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says - MarketScreener

Jun 10, 2025

Jun 10, 2025

ADAR1 Demands Bigger Payouts From Keros Therapeutics - Finimize

Jun 10, 2025

Jun 10, 2025

BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32 - marketscreener.com

Jun 10, 2025

Jun 10, 2025

KROS: Keros Therapeutics Receives Downgrade from B of A Securities | KROS Stock News - GuruFocus

Jun 10, 2025

Jun 10, 2025

Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst - GuruFocus

Jun 10, 2025

Jun 10, 2025

Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst | KROS Stock News - GuruFocus

Jun 10, 2025

Jun 10, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 10, 2025

Jun 09, 2025

Keros Therapeutics to return $375 million to shareholders By Investing.com - Investing.com South Africa

Jun 09, 2025

Jun 09, 2025

ADAR1 Capital Management Calls For Keros Therapeutics To Return $475 Mln To Stockholders By Q3 - marketscreener.com

Jun 09, 2025

Jun 09, 2025

Keros Directors Face Massive Shareholder Revolt: ADAR1 Pushes for $475M Dividend and Board Overhaul - Stock Titan

Jun 09, 2025

Jun 09, 2025

Keros Therapeutics (KROS) to Return $375M Capital to Shareholders | KROS Stock News - GuruFocus

Jun 09, 2025

Jun 09, 2025

Keros Therapeutics Concludes Strategic Alternatives Review - TipRanks

Jun 09, 2025

Jun 09, 2025

Keros to Return $375 Million to Shareholders Following Strategic Review - marketscreener.com

Jun 09, 2025

Jun 09, 2025

Keros Announces Return of $375 Million in Excess Capital to Stockholders - The Manila Times

Jun 09, 2025